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was 11.0 years, treatment duration 4.4 years, and height SDS 
gain 0.83 (95% confidence interval 0.49–1.17). Respective 
ages, GH treatment durations and height SDS gains for
GeNeSIS patients prepubertal at baseline ( n = 42) were 9.2 
years, 6.0 years and 1.19 (0.76–1.62), and for the clinical trial 
cohort they were 9.2 years, 6.0 years and 1.25 (0.92–1.58). No 
new GH-related safety concerns were identified.  Conclu-
sion: Patients with SHOX deficiency who had started GH 
treatment before puberty in routine clinical practice had a 
similar height gain to that of patients in the clinical trial on 
which approval for the indication was based, with no new 
safety concerns.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Growth is influenced by many factors, both genetic 
and environmental, and short stature is a frequent reason 
for referral to a paediatric endocrinologist. One of the 
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 Abstract 
 Background/Aims: To assess auxological and safety data for 
growth hormone (GH)-treated children with SHOX deficien-
cy.  Methods: Data were examined for GH-treated SHOX-de-
ficient children ( n = 521) from the observational Genetics 
and Neuroendocrinology of Short Stature International 
Study (GeNeSIS). For patients with near-adult height infor-
mation, GeNeSIS results ( n = 90) were compared with a clin-
ical trial ( n = 28) of SHOX-deficient patients. Near-adult 
height was expressed as standard deviation score (SDS) for 
chronological age, potentially increasing the observed ef-
fect of treatment.  Results: Most SHOX-deficient patients in 
GeNeSIS had diagnoses of Leri-Weill syndrome ( n = 292) or 
non-syndromic short stature ( n = 228). For GeNeSIS patients 
with near-adult height data, mean age at GH treatment start 
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many genes involved in statural growth is the short stat-
ure homeobox-containing  (SHOX) gene located in the 
pseudoautosomal region (PAR1) of the X and Y chromo-
somes  [1, 2] . This gene may be affected by mutations and 
deletions in the coding region and in the enhancer re-
gions  [1–5] . Deficiency of the gene product results in a 
broad spectrum of phenotypic characteristics, including 
variable degrees of impaired growth  [2, 6–8] . In addition 
to short stature, children with SHOX deficiency may also 
have skeletal anomalies consistent with mesomelic skel-
etal dysplasia, including short forearms and lower legs, 
and bowing of the forearms  [2, 7–10] . Such clinical signs 
are typical of Leri-Weill syndrome (LWS); however, 
some children with SHOX deficiency may have no evi-
dence of skeletal dysplasia, identifiable clinical anoma-
lies, or other definable causes for their short stature
 [8–10] .
 Girls and women with Turner syndrome lack all or 
part of the second sex chromosome and, therefore, have 
only one copy of  SHOX ; this haploinsufficiency underlies 
a substantial portion of the short stature seen in patients 
with Turner syndrome  [11] . Many studies have demon-
strated increased adult height following growth hor-
mone (GH) therapy in patients with Turner syndrome 
 [12–16] . For this reason, GH therapy was examined in 
patients with non-Turner syndrome SHOX deficiency, 
and several studies have now shown that GH can have a 
positive effect on the growth of SHOX-deficient patients 
 [16–19] .
 Approval for the indication of GH treatment of short 
stature due to SHOX deficiency was based on data from 
the 2-year randomised treatment phase of a single clinical 
trial  [17] . After completion of this randomised phase, all 
participants were offered GH therapy until attainment of 
near-adult (final) height  [16] . It is important to determine 
whether results from clinical trials are matched by subse-
quent outcomes in routine clinical practice. Observation-
al programmes, such as the Genetics and Neuroendocri-
nology of Short Stature International Study (GeNeSIS), 
are carried out to assess safety and effectiveness outcomes 
of children with growth disorders, with or without GH 
treatment. The present study aimed to analyse GeNeSIS 
data for patients with short stature associated with SHOX 
deficiency and to evaluate long-term effects of GH thera-
py on safety and near-adult height. Results for patients 
who achieved near-adult height during this observational 
study were assessed in relation to results from the previ-
ously published clinical trial of GH-treated SHOX-defi-
cient patients  [16, 17] .
 Methods 
 Patient Populations 
 GeNeSIS (ClinicalTrials.gov: NCT 01088412) was a prospec-
tive multinational, open-label, paediatric surveillance programme 
designed to examine the long-term safety and efficacy of GH (Hu-
matrope ® , Eli Lilly and Company, Indianapolis, IN, USA) admin-
istered for treatment of short stature. Patients were enrolled from 
March 1999 to September 2013. Among the causes of short stature, 
the database includes paediatric patients who have received GH 
therapy for short stature associated with SHOX deficiency. SHOX 
deficiency was diagnosed by investigators on the basis of clinical 
signs of LWS and/or molecular genetic data available at the time 
of presentation or study enrolment. Patients enrolled in GeNeSIS 
and diagnosed by investigators as having Turner syndrome were 
not included in the present analysis.
 Because GeNeSIS was an observational study, all diagnostic 
and treatment decisions, including study enrolment and GH dose, 
were made at the discretion of the participating investigator, in ac-
cordance with standard paediatric endocrinology practice. The 
only specific eligibility criterion in GeNeSIS was that patients had 
open epiphyses.
 In the clinical trial (NCT 00190658), carried out from February 
2000 to September 2010, patients with SHOX deficiency and short 
stature were randomised to be either treated with GH (0.05 mg/kg/
day) or untreated for the first 2 years  [17] . At the end of the ran-
domised period, all patients were offered GH treatment (0.05 mg/
kg/day) until near-adult height was attained or until study closure. 
All enrolled patients were at least 3 years of age and were prepu-
bertal (girls: Tanner stage 1 breast development; boys: Tanner 
stage 1 genital development and testicular volume  ≤ 2 mL) at the 
start of GH therapy; other criteria for enrolment and patient char-
acteristics have been described previously  [16, 17] .
 Both the GeNeSIS observational study and the clinical trial in-
cluded patients who were followed until they achieved near-adult 
(final) height. It was possible for patients in the clinical trial to 
subsequently be enrolled in GeNeSIS; therefore, it was ascertained 
that such patients were excluded from analysis within the GeNeSIS 
cohort and only included in the clinical trial cohort for safety as-
sessments and analysis of patients who achieved near-adult height. 
Patients who had entered puberty at GH initiation were not ex-
cluded from GeNeSIS participation, whereas all patients in the 
clinical trial were prepubertal when starting GH. Therefore, a sub-
group of patients in GeNeSIS who were prepubertal at the time of 
GH initiation and who had near-adult height data available was 
also assessed.
 The clinical trial protocol was approved by all appropriate local 
ethics review committees and the GeNeSIS protocol adhered to the 
applicable regulatory requirements in the participating countries, 
with appropriate institutional review board approvals. In both the 
observational study and the clinical trial, written informed consent 
for data collection, processing and publication was provided by the 
parents or a legal guardian for each child, in accordance with na-
tional and local regulations. Both studies were performed accord-
ing to the ethical principles of the Declaration of Helsinki.
 Study Evaluations 
 Baseline data collected at the entry to GeNeSIS included medi-
cal history, physical examination, laboratory values and pubertal 
status, as provided by the attending physician. Medical history in-
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cluded the investigator-defined diagnosis of the cause of short stat-
ure, previous laboratory data and pre-existing medications. Base-
line clinical variables included height, weight, parental heights (for 
the calculation of the genetic target height [sex-adjusted average of 
parental heights]) and bone age. Pubertal stage was evaluated ac-
cording to the Tanner classification. Height, weight and pubertal 
stage were documented at follow-up visits.
 Baseline data in the clinical trial included medical history, 
height, weight, parental heights and bone age. All patients had 
SHOX deficiency confirmed by centralised genetic analysis of the 
 SHOX gene  [8] . Investigators also reported the clinical phenotype, 
with categorisation as either having LWS or non-syndromic short 
stature. At the start of GH therapy, all patients were prepubertal 
(Tanner stage 1), had no evidence of GH deficiency or resistance 
and were not taking any growth-influencing medications. Height, 
weight and pubertal development changes were evaluated at fol-
low-up visits.
 Patients from GeNeSIS and the clinical trial were considered to 
have reached near-adult height (final height) during follow-up if 
they attained one of the following criteria: height velocity <2 cm/
year, X-ray of the hand showing closed epiphyses or bone age >14 
years for girls or >16 years for boys. Bone age was assessed from 
radiographs of the left hand and wrist, which were read using 
Greulich and Pyle standards  [20] .
 The clinical trial predominantly enrolled patients from central 
European countries; therefore, standard deviation scores (SDS) for 
height were calculated for both GeNeSIS and the clinical trial using 
data from a central European reference population  [21] . Near-
adult height was expressed as height SDS for chronological age at 
the time of the measurement, including when adult height was 
considered as attained, which could potentially increase the ob-
served effect of treatment but is a well-accepted method for SDS 
calculation. Body mass index SDS was determined from European 
reference data  [22] .
 Safety analysis for inclusion in this report was based on adverse 
events reported for patients who received GH therapy. Serious ad-
verse events (SAEs) were defined as any event that resulted in 
death, hospitalisation, persistent or significant disability, or con-
genital anomaly in the offspring of a treated patient, were consid-
ered life-threatening or were significant for another reason in the 
opinion of the investigator. Treatment-emergent adverse events 
(TEAEs) were assessed for patients who had at least one follow-up 
visit after starting GH therapy and were defined as events that first 
occurred or worsened in severity. All adverse events were catego-
rised according to the Medical Dictionary for Regulatory Author-
ities (MedDRA, version 11.0).
 Genetic Analyses 
 Patients enrolled in GeNeSIS could have a diagnosis of SHOX 
deficiency on the basis of clinical signs, with no requirement to 
have a proven  SHOX gene alteration, and underwent genetic test-
ing only at the discretion of the investigator. Therefore, the mo-
lecular technique varied according to the laboratory carrying out 
the genetic testing. In France, the analyses were carried out by the 
Necker-Enfants Malades hospital group, Paris, as previously de-
scribed  [23] . Samples from other European countries were mainly 
analysed at Bioscientia, Germany, although some were analysed at 
other local laboratories; samples from US sites were analysed at 
Esoterix Endocrinology, Calabasas Hills, CA, USA. Analysis of the 
downstream and upstream enhancer regions for the  SHOX gene 
was carried out for a limited number of patients who had entered 
GeNeSIS more recently.
 In the clinical trial, all patients were required to have a demon-
strated  SHOX gene alteration, based on central laboratory analysis 
 [8] . The enhancer domains for the  SHOX gene had not been iden-
tified at the time of screening for the clinical trial and were, there-
fore, not analysed.
 Statistics 
 Data for patients with SHOX deficiency in GeNeSIS were ana-
lysed using descriptive statistics. Results for continuous variables 
are presented as means ± SD with 95% confidence intervals (CIs). 
Information on categorical variables is presented as number of pa-
tients and percentage of the relevant total population. Safety data 
were assessed for all patients who received GH treatment in both 
GeNeSIS and the clinical trial. Near-adult heights were assessed 
using mean and 95% CI of height SDS for age at the time of mea-
surement.
 Results 
 Baseline Data for Patients with SHOX Deficiency in 
GeNeSIS 
 At the March 2014 data lock for this report, the
GeNeSIS database contained evaluable information for 
21,577 GH-treated paediatric patients, including 521 pa-
tients (314 female, 207 male) with a diagnosis of SHOX 
deficiency enrolled between 2000 and 2013. The majority 
of the GH-treated SHOX-deficient patients were from 
Germany ( n = 197) and France ( n = 180), followed by the 
USA (n = 61), Spain ( n = 25) and Czech Republic ( n = 20), 
with the remainder spread among 11 other countries.
 Among the 521 patients, the numbers with an investi-
gator-provided diagnosis of either LWS (56%) or non-
syndromic short stature (44%) are shown in  Figure 1 , to-
gether with available information on identified gene de-
fects. Molecular alterations affecting the  SHOX gene, as 
described by the investigator, were reported for 207 (71%) 
of the 292 patients with a diagnosis of LWS. Of these, 194 
patients (66%) had a reported molecular alteration en-
compassing the  SHOX gene, with or without a reported 
alteration in the PAR1, and 12 (4%) had identified altera-
tions in the regulatory regions of the  SHOX gene only; the 
nature of the genetic alteration was not specified for 1 
patient. The majority of the  SHOX alterations were com-
plete or partial deletions involving the coding region 
(153/207 = 74%), 16% were missense or nonsense muta-
tions and 1% were partial duplications. No alteration of 
the  SHOX gene or PAR1 was identified for 54 (18%) of 
the patients with LWS phenotype. Of the 228 patients 
with non-syndromic SHOX deficiency, alterations in the 
 SHOX gene were identified in 218, comprising deletions 
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for 124 (57%), mutations for 67 (31%), and other varia-
tions for 27 (12%).
 Baseline characteristics of all patients with SHOX de-
ficiency in GeNeSIS are summarised in  Table 1 . Mean age 
at the start of GH treatment was 9.4 ± 3.2 (95% CI 9.1–9.6) 
years. Mean height SDS was  − 3.01 ± 0.77 (95% CI  − 3.08 
to  − 2.94), and mean initial GH dose was 0.30 ± 0.09 (95% 
CI 0.29–0.31) mg/kg/week.
 Safety Information 
 For 514 patients with SHOX deficiency in GeNeSIS, 
with available information, mean duration of follow-up 
was 2.8 ± 2.0 years. One death was reported and 3 patients 
discontinued due to adverse events. In the clinical trial, 
49 patients received GH for a mean duration of 7.0 ± 1.8 
years for those initially randomised to GH ( n = 26) and 
4.8 ± 2.0 years for those randomised to be untreated with 
GH for the first 2 years ( n = 23); there were no reported 
deaths or discontinuations due to adverse events.
 In GeNeSIS, 14 SAEs were reported for 12 patients 
(appendicitis [ n = 2], chronic renal failure [ n = 2], ade-
noidectomy, death, hypertension, ligament injury, limb 
operation, lower limb fracture, neoplasm recurrence, os-
teomyelitis, post-streptococcal glomerulonephritis, and 
spondylolisthesis). The SAE reported as death was a girl 
diagnosed with LWS, with no identified  SHOX gene de-
fect; she received a kidney transplant following chronic 
renal failure, had received GH for approximately 2 years 
and 4 months, and died 18 months after discontinuing 
GH. The neoplasm recurrence was a relapse of pilocytic 
Regulatory region alteration
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 Fig. 1. Summary of specific diagnoses and  SHOX gene alterations 
of patients in GeNeSIS with a diagnosis of SHOX deficiency. As-
signments of genetic alterations are based on the available report-
ed data and reflect the classification of individual patients by their 
clinician.  a Included 1 patient with a gene alteration that was not 
specified.  b Included  SHOX deletion ( n = 106 [51% of 207 with 
SHOX alterations]),  SHOX +  PAR1 deletion ( n = 35 [17%]),  SHOX 
partial deletion ( n = 9 [4%]) and  SHOX +  PAR1 partial deletion
( n = 3 [1%]).  c Included  SHOX deletion ( n = 100 [46% of 218 with 
SHOX alterations]),  SHOX +  PAR1 deletion ( n = 19 [9%]),  PAR1 
deletion ( n = 1 [<1%]) and  SHOX partial deletion ( n = 4 [2%]). 
LWS, Leri-Weill syndrome;  SHOX,  short stature homeobox-con-
taining gene. 
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astrocytoma approximately 1 year and 11 months after 
GH initiation.
 In the clinical trial, 10 SAEs were reported for 6 pa-
tients (epilepsy [ n = 2], abdominal pain, acute seizure, 
appendicitis, arthritis, Crohn disease, inguinal hernia, 
tonsillar hypertrophy, and vomiting). The 2 epilepsy 
events and the acute seizure all occurred in 1 patient.
 No TEAEs were reported for 397 (80%) of the 495 pa-
tients with SHOX deficiency in GeNeSIS who had at least 
one follow-up visit after starting GH therapy. A TEAE 
was reported for 98 patients (20%); the most frequent 
were precocious puberty and arthralgia ( Table 2 ). For the 
49 patients in the clinical trial, 43 (87.8%) reported at least 
1 TEAE; the majority were for common childhood ill-
nesses, particularly infections and infestations reported 
for 32 patients (65%). Scoliosis was reported for 5 (10%) 
patients in the clinical trial and 2 (0.4%) patients in
GeNeSIS. There were no reports of diabetes mellitus in 
the GH-treated patients with SHOX deficiency in either 
study.
 Near-Adult Height Data 
 Near-adult height data were available at the time of 
analysis for 90 GH-treated patients with SHOX deficien-
cy in GeNeSIS, 42 of whom were prepubertal at baseline; 
near-adult height data were available for 28 patients in the 
clinical trial, all of whom were prepubertal at baseline. 
The genotype and phenotype data for these patients are 
shown in  Table 3 . In both GeNeSIS and the clinical trial, 
the majority of patients with available near-adult height 
data had a diagnosis of LWS. For patients in GeNeSIS 
with genetic data available, the proportions with an iden-
tified mutation, deletion or duplication were very similar 
to the proportions identified during screening for the 
clinical trial ( Table 3 ).
 Patient characteristics, auxological parameters and 
GH treatment details at GH initiation and near-adult 
height are summarised in  Table 4 . The mean age at GH 
start was greater for the full group of 90 patients with 
near-adult height data in GeNeSIS than for the patients 
in the clinical trial; however, the mean age of the 42 pre-
pubertal patients in this subgroup of GeNeSIS was similar 
to that of the patients in the clinical trial ( Table 4 ). Mean 
age at near-adult height for both the full group and the 
prepubertal subgroup of patients in GeNeSIS was similar 
to that of the patients in the clinical trial. Thus, mean 
treatment duration was shorter for the complete GeNeSIS 
cohort with near-adult height data than for patients in the 
 Table 1.  Characteristics at the start and height gain after 1 year of 
GH treatment of patients with SHOX deficiency in the 
GeNeSIS observational programme
Children with SHOX 
deficiency (n = 521)a
Female/male 314 (60.3)/207 (39.7)
Tanner stage 1 (female/male), % 69.0/83.6
Age, years 9.4 ± 3.2 (9.1 to 9.6)
Bone age delay, years –0.9 ± 1.2 (–1.1 to –0.8)
Height SDS –3.01 ± 0.77 (–3.08 to –2.94)
Target height SDS –1.14 ± 0.93 (–1.23 to –1.06)
Height SDS – target height SDS –1.87 ± 1.05 (–1.96 to –1.77)
GH dose, mg/kg/week 0.30 ± 0.09 (0.29 to 0.31)
First year gain in height SDSb 0.53 ± 0.51 (0.47 to 0.59)
 Data show number of patients (% of total) or mean ± SD (95% 
CI). CI, confidence interval; SD, standard deviation; SDS, standard 
deviation score; SHOX, short stature homeobox-containing gene.
a Total number of patients with evaluable data, but patient 
numbers may be lower for individual parameters. b Evaluable for 
277 patients. 
 Table 2. Reported SAEs and TEAEs during GH treatment of 
patients with SHOX deficiency in GeNeSIS and the clinical trial
GeNeSIS Clinical trial
Number of GH-treated patients 521 49
Patients with ≥1 SAE 12 (2.3%) 6 (12.2%)
Number of GH-treated patients 
with  follow-up 495 49
Patients with ≥1 TEAE 98 (19.8%) 43 (87.8%)
TEAEs reported most frequentlya
Precocious puberty 13 (2.6%) 1 (2.0%)
Arthralgia 12 (2.4%) 6 (12.2%)
Headache 8 (1.6%) 9 (18.4%)
Hypothyroidism 6 (1.2%) 1 (2.0%)
Back pain 5 (1.2%) 4 (8.2%)
Madelung deformity 2 (0.4%) 8 (16.3%)
Nasopharyngitis 1 (0.2%) 7 (14.3%)
Ear infection 1 (0.2%) 6 (12.2%)
Cough 1 (0.2%) 6 (12.2%)
Congenital bowing of long bonesb 0 9 (18.4%)
Vomiting 0 6 (12.2%)
GH, growth hormone; SAE, serious adverse event; SHOX, 
short stature homeobox-containing gene; TEAE, treatment-
emergent adverse event.
a MedDRA preferred terms; events reported in >1% of patients 
in GeNeSIS or >12% of clinical trial patients. b MedDRA preferred 
term states congenital, reflecting the initial clinical observation of 
Madelung deformity during study participation.
 Outcomes of GH-Treated Children with 
SHOX Deficiency 
Horm Res Paediatr 2017;87:42–50
DOI: 10.1159/000452973
47
clinical trial, whereas GeNeSIS patients who started GH 
when prepubertal had a treatment duration similar to 
that of patients in the clinical trial. Initial and last report-
ed doses of GH were lower for the full cohort of GeNeSIS 
patients with near-adult height data than for patients in 
the clinical trial. For the GeNeSIS patients who were pre-
pubertal at the GH start, the initial GH dose was similar 
to that for the patients in the clinical trial, but the last re-
ported dose was lower.
 Height SDS at baseline and near-adult height, as well 
as change in height SDS are shown in  Figure 2 . Mean 
change in height SDS from GH start to near-adult height 
was 0.83 (95% CI 0.49–1.17) for the full GeNeSIS cohort 
and 1.19 (95% CI 0.76–1.62) for the prepubertal subgroup 
in GeNeSIS, compared with 1.25 (95% CI 0.92–1.58) for 
patients in the clinical trial. At the time of near-adult 
height measurement, 53% of the patients in GeNeSIS and 
57% of the patients in the clinical trial had height above 
the lower limit of the normal range (>–2 SDS).
 Discussion 
 Among patients enrolled in the GeNeSIS observation-
al study and treated with GH in routine clinical practice, 
a diagnosis of SHOX deficiency was reported by physi-
cians for 521 patients. For 56% of these patients the diag-
nosis was reported as LWS, and for 44% the phenotype 
was reported to be “non-syndromic” SHOX deficiency 
(also known as “idiopathic” short stature). This pheno-
type distribution was similar to the approximately equal 
proportions of LWS versus idiopathic short stature for 
the total cohort included in the clinical trial  [17] . There 
was also 1 GH-treated patient in GeNeSIS with a diagno-
sis of Langer mesomelic dysplasia, the homozygous form 
of SHOX deficiency; although GH treatment may have 
limited effectiveness in promoting height gain in patients 
with this condition, the patient was included in the anal-
ysis in reflection of the real-world nature of data from an 
observational study. All of the patients with SHOX defi-
ciency had severe growth impairment at baseline, and GH 
treatment for 1 year was associated with a mean height 
SDS gain of 0.53.
 The genetic information in GeNeSIS was as provided 
by the investigators, with different analysis techniques 
used over a long enrolment period. However, the data 
showed that the majority of the genetic alterations for pa-
tients in GeNeSIS were complete or partial deletions of 
the  SHOX gene. Consistent with previous reports, en-
rolled patients more commonly had deletions of the 
 Table 3. Phenotype and genotype information for patients with 
SHOX deficiency for whom near-adult height data were reported 
at the time of analysis
GeNeSIS
(n = 90)
Clinical trial
(n = 28)
Phenotype
Leri-Weill syndrome 56 (62%) 17 (61%)
Non-syndromic short stature 34 (38%) 11 (39%)
Genotype
Deletion 43 (48%) [77%] 22 (79%)
Mutation 9 (10%) [16%] 5 (18%)
Translocation 1 (1%) [2%] 0
Duplication 1 (1%) [2%] 1 (4%)
Regulatory region alteration 2 (2%) [4%] N/A
No identified alteration/no test 34 (38%) N/A
Data show numbers of patients with phenotype/genotype 
(percentage of total number of patients for whom near-adult 
height was reported) [percentage of the 56 GeNeSIS patients with 
identified genetic alteration for whom near-adult height was 
reported]. Assignments of genetic alterations were based on the 
available reported data and reflect the classification of individual 
patients by their clinician. N/A, not applicable; SHOX, short 
stature homeobox-containing gene.
2 Baseline
H
ei
gh
t S
D
S
1
0
GeNeSIS
–1
–2
–3
–4
Near-adult height Change
GeNeSIS
prepubertal
Clinical trial
 Fig. 2. Height standard deviation score at the start of growth hor-
mone treatment and at near-adult height, with change from base-
line to near-adult height, for patients who attained near-adult 
height during GeNeSIS follow-up, patients who were prepubertal 
(Tanner 1) and reached near-adult height during GeNeSIS, and 
those who reached near-adult height in the clinical trial  [16] . Bars 
show means with 95% confidence intervals; dashed line indicates 
lower limit of normal height range. SDS, standard deviation score. 
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 SHOX gene than single base mutations  [2, 24, 25] . Preva-
lence of deletions versus point mutations was greater in 
the patients with LWS phenotype than in those with the 
non-syndromic phenotype, suggesting that the pheno-
type may correlate to some extent with the magnitude of 
the genetic alteration. Alterations in the  SHOX regulatory 
region were only found in 5–6% of the patients with LWS 
and non-syndromic SHOX deficiency (18% of patients 
with LWS and 9% of those with non-syndromic SHOX 
deficiency had deletions that also extended to other parts 
of PAR1, potentially including regulatory elements). The 
relatively small number of patients in GeNeSIS with iden-
tifiable alterations in the regulatory regions of the  SHOX 
gene  [26, 27] is most likely due to the fact that, during the 
enrolment period from 1999 to 2013, screening for al-
terations in enhancer elements was not uniformly per-
formed in genetic laboratories  [6, 8, 25, 28] .
 Analysis of the GeNeSIS patients known to be prepu-
bertal at GH initiation showed that they had a similar 
mean height SDS gain from the start of GH treatment to 
that seen for the patients in the clinical trial. In both co-
horts, substantial mean height SDS gains of approximate-
ly 1.2 (equivalent to approximately 8 cm) were observed. 
Apart from the previous report of the clinical trial, the 
only other study to date that has reported final height/
near-adult height data for GH-treated patients with 
SHOX deficiency found a mean height SDS gain of 0.6 in 
a group of 5 peripubertal patients who were treated with 
a gonadotropin-releasing hormone analogue for pubertal 
suppression and started GH at a mean age of 11.6 years 
 [29] . These findings suggest that, similar to other short 
stature indications for GH treatment, height gain is great-
er when GH is initiated early, particularly before onset of 
puberty  [30, 31] . However, the use of height SDS for 
chronological age of the near-adult height measurement 
in children with a mean age of 15.7 years may not accu-
rately measure the true adult height SDS.
 Identification of patients with potential SHOX defi-
ciency when prepubertal can be challenging, especially in 
boys, because most young children with SHOX deficiency 
lack specific clinical signs such as high-arched palate or 
Madelung deformity  [32, 33] . Careful measurement of 
body proportions can elicit more subtle markers of SHOX 
deficiency, such as increased sitting height-to-height ra-
tio and reduced extremities-to-trunk ratio  [32, 34] . Fur-
thermore, meticulous examination of the parents for 
Madelung deformity, complemented by forearm X-rays 
of the child, can facilitate an earlier diagnosis of SHOX 
deficiency in a prepubertal child with non-syndromic 
short stature  [2] .
 The phenotypes and genotypes were very similar
for the prepubertal patients with SHOX deficiency in 
GeNeSIS and the patients in the clinical trial. Thus, the 
similar height gains observed for the prepubertal GeNe-
SIS and clinical trial cohorts would indicate that the clin-
ical trial data on which the relevant approval was based 
are reasonably generalisable to that of patients with SHOX 
deficiency in routine clinical practice, when GH is initi-
ated before the start of puberty.
 Table 4. Demographics, auxology and GH treatment profile at baseline (GH initiation) and at near-adult height for all patients in 
GeNeSIS, the subgroup of patients in GeNeSIS who were prepubertal (Tanner stage 1) at GH start, and patients in the clinical trial, for 
whom NAH was attained during follow-up
 GeNeSIS Clinical trial 
(n = 28)all (n = 90) prepubertal (n = 42)
Female, n (%) 59 (65.6) 32 (76.2) 15 (53.6)
Age at GH initiation, years 11.0 ± 2.4 (10.5 to 11.5) 9.2 ± 2.2 (8.6 to 9.9) 9.2 ± 2.4 (8.3 to 10.2)
Age at NAH, years 15.7 ± 1.4 (15.4 to 16.0) 15.5 ± 1.3 (15.1 to 15.9) 15.5 ± 1.3 (15.0 to 16.0)
Bone age delay at baseline, years –0.6 ± 1.5 (–1.0 to –0.2) –0.9 ± 1.6 (–1.5 to –0.3) –0.9 ± 0.7 (–1.2 to –0.7)
Height SDS at baseline –3.01 ± 0.87 (–3.19 to –2.83) –3.20 ± 0.88 (–3.48 to –2.93) –3.20 ± 0.77 (–3.50 to –2.90)
Target height SDS –1.14 ± 0.89 (–1.33 to –0.95) –1.21 ± 0.77 (–1.46 to –0.97) –1.6 ± 0.9 (–1.92 to –1.19)
NAH SDS – target height SDS –0.96 ± 1.41 (–1.28 to –0.64) –0.78 ± 1.21 (–1.18 to –0.38) NA
GH dose at start, mg/kg/week 0.32 ± 0.10 (0.30 to 0.34) 0.34 ± 0.08 (0.31 to 0.37) 0.36 ± 0.02 (0.35 to 0.37)
GH dose last reported, mg/kg/week 0.33 ± 0.10 (0.30 to 0.35) 0.33 ± 0.10 (0.30 to 0.36) 0.38 ± 0.02 (0.37 to 0.38)
Treatment duration, years 4.40 ± 2.33 (3.91 to 4.90) 5.98 ± 2.15 (5.31 to 6.65) 6.02 ± 2.01 (5.24 to 6.79)
Data show mean ± SD (95% CI). CI, confidence interval; GH, growth hormone; NA, not available; NAH, near-adult height; SD, 
standard deviation; SDS, standard deviation score; SHOX, short stature homeobox-containing gene.
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 Analysis of safety information from the GH-treated 
patients with SHOX deficiency in GeNeSIS did not indi-
cate any new concerns. The proportion of patients for 
whom at least 1 TEAE was reported was substantially 
greater in the clinical trial than in GeNeSIS; this was not 
unexpected because adverse event reporting was mandat-
ed in the clinical trial, whereas patients and investigators 
are less likely to report adverse events during routine clin-
ical management and treatment. There was no evidence 
for excessive bone maturation or any worsening of dys-
morphic or skeletal features. Scoliosis was reported at a 
low incidence: 5 cases in the clinical trial, of which 1 was 
considered by the investigators to be possibly related to 
GH treatment, and 2 cases reported in the GeNeSIS pop-
ulation, both of which were considered to be unrelated to 
GH treatment. Although precocious puberty was report-
ed for 13 patients (2.6%) in GeNeSIS, further investiga-
tion showed that most of these cases did not meet the ac-
cepted criteria for diagnosis (i.e. breast development be-
fore 8 years of age in girls and testicular enlargement 
before 9 years of age in boys).
 In conclusion, among patients who were treated with 
GH for short stature associated with SHOX deficiency in 
GeNeSIS, 56% had an investigator-provided diagnosis of 
LWS and 44% had a diagnosis of non-syndromic SHOX 
deficiency. These proportions for clinical phenotype of 
patients in routine clinical practice were similar to those 
for patients identified in the defining clinical trial  [16] . 
The majority of identified alterations involving the  SHOX 
gene were deletions, and a minority of patients had mis-
sense and nonsense mutations, duplications and translo-
cations. Near-adult height gain for patients in GeNeSIS 
who were prepubertal at GH start was similar to that for 
patients in the clinical trial, indicating that the clinical 
trial results were broadly reflective of the response of pa-
tients with SHOX deficiency to GH treatment under stan-
dard clinical conditions. It remains important to identify 
patients with short stature due to SHOX deficiency as ear-
ly as possible, because GH treatment is most effective 
when started at a young age.
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